PHASE IB TRIAL OF IMO-2055 IN COMBINATION WITH 5-FU, CISPLATIN AND CETUXIMAB IN 1ST-LINE PTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN)

被引：0
|
作者：
Machiels, J. P. [1 ]
Kaminsky, M. C. [2 ]
Keller, U. [3 ]
Bruemmendorf, T. H. [4 ]
Goddemeier, T. [5 ]
Forssman, U. [6 ]
Delord, J. P. [7 ]
机构：
[1] Clin Univ St Luc, B-1200 Brussels, Belgium
[2] Ctr Alexis Vautrin, Dept Med Oncol, Nancy, France
[3] Tech Univ Munich, Med Klin 3, Munich, Germany
[4] Univ Klinikum Aachen, Aachen, Germany
[5] Merck KGaA, Global Clin Operat Global Biostat, Darmstadt, Germany
[6] Merck Serono SA, Global Clin Dev Unit Oncol, Geneva, Switzerland
[7] Ctr Claudius Regaud, Clin Resarch Unit, Toulouse, France
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：342 / 342
页数：1
相关论文
共 50 条
  • [21] Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence
    Ham, Janneke C.
    van Meerten, Esther
    Fiets, W. Edward
    Beerepoot, Laurens V.
    Jeurissen, Frank J. F.
    Slingerland, Marije
    Jonker, Marianne A.
    Husson, Olga
    van der Graaf, Winette T. A.
    van Herpen, Carla M. L.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2020, 42 (05): : 828 - 838
  • [22] Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A phase Ib randomized phase II study versus single agent MTX
    Ham, J.
    Meerten, E.
    Fiets, E.
    Mc Haaglanden, F. Jeurissen
    Slingerland, M.
    van der Graaf, W. T. A.
    van Herpen, C. M. L.
    Beerepoot, L. V.
    ANNALS OF ONCOLOGY, 2018, 29
  • [23] A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Dunn, Lara
    Ho, Alan Loh
    Eng, Juliana
    Michel, Loren S.
    Fetten, James Vincent
    Warner, Elizabeth
    Kriplani, Anuja
    Zhi, Wanqing Iris
    Ng, Kenneth K.
    Haque, Sofia
    Pfister, David G.
    Sherman, Eric Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
    Tsakonas, Georgios
    Specht, Lena
    Kristensen, Claus Andrup
    Moreno, Maria Herlestam Calero
    Haugen Cange, Hedda
    Soderstrom, Karin
    Friesland, Signe
    CANCERS, 2020, 12 (11) : 1 - 11
  • [25] An analysis of toxicity in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving cetuximab, fluorouracil and cisplatin alone or with docetaxel in a phase II clinical trial (CeFCiD)
    Knoedler, M.
    Dietz, A.
    Gauler, T.
    Stoehlmacher, J.
    Gruenwald, V
    Rethwisch, V
    Frickhofen, N.
    Haxel, B.
    Schroeder, M.
    Knipping, S.
    Maschmeyer, G.
    Guntinas-Lichius, O.
    Keilholz, U.
    ONKOLOGIE, 2012, 35 : 153 - 153
  • [26] RESULTS OF TPEX (DOCETAXEL, CISPLATIN, CETUXIMAB) REGIMEN USE IN FIRST LINE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) IN A SINGLE INSTITUTION
    Even, C.
    Bobillot, B.
    Mayache-Badis, L.
    Ferrand, F. R.
    Lezghed, N.
    Bidault, F.
    Auperin, A.
    Temam, S.
    Janot, F.
    Schilf, A.
    Guigay, J.
    ANNALS OF ONCOLOGY, 2014, 25
  • [27] Phase 2 trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Obara, Grzegorz
    Sun, Jichao
    Loo, Deryk
    Bohac, Gerry C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] A phase II study of vinorelbine GIRL), cisplatin (CDDP) and 5-Fluorouracil (FU) in patients (PTS) with locally advanced recurrent, and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Guillem, V
    Muñoz, MA
    Yaya, R
    Soriano, V
    Climent, MA
    Gaspar, C
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S176 - S176
  • [29] Early activity and biomarker evaluation of NT219 in combination with cetuximab in a Phase 1/2 study of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Rosenberg, Ari J.
    Kato, Shumei
    Johnson, Daniel
    Popovtzer, Aron
    Chiu, Vi K.
    Geva, Ravit
    Ben-David, Hava
    Meirson, Tomer
    Schickler, Michael
    Reuveni, Hadas
    CANCER RESEARCH, 2024, 84 (06)
  • [30] MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with Docetaxel, Cisplatin and 5-FU (DCF) in induction for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
    Even, C.
    Texier, M.
    Le Tourneau, C.
    Marabelle, A.
    Chaput, N.
    Adam, J.
    Paci, A.
    Broutin, S.
    Ferte, C.
    Breuskin, I.
    Cupissol, D.
    Fayette, J.
    ANNALS OF ONCOLOGY, 2017, 28
12345